Smithkline Beecham Corporation

Glaxosmithkline LLC

Smithkline Corporation

Michael J Neeb

Scott Kevin Thompson

James S Frazee

Lara Kallander

Chun Ma

Clark A Sehon

Krista B Goodman

Gren Z Wang

Andrew Q Viet

Ajita Bhat

Joseph Marino

William Edward Bondinell

Robert Anthony Mook

Thomas Wen-Fu Ku

Joseph P Marino, Jr

James Michael Salovich

Robert A Stavenger

Ning Wang

Ronda Davis-Ward

The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

Morpholinyl and pyrrolidinyl analogs

The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Pyrimidine compounds

The present invention relates to 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid and its pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

Disclosed is a compound having the formula: 

Compounds and methods

Disclosed is a compound of having the formula: 

Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists 

Amide compounds and methods of using the same

This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

Growing community of inventors

King of Prussia, PA, United States of America

Michael J Neeb